常规治疗加用左西孟旦治疗慢性进展性心力衰竭的疗效  

Efficacy of routine therapy combined levosimendan in the treatment of chronic progressive heart failure

作　　者：吴林栩 王卿语 叶张章 郭琰 WU Lin-xu;WANG Qing-yu;YE Zhang-zhang;GUO Yan(First Cadet Brigade,Air Force Military Medical University,Xi＇an 710032,Shaanxi,China;Department of Cardiology,Xi＇an Medical College,Xi＇an 710032,Shaanxi,China;Department of Cardiology,Qionghai People＇s Hospital,Qionghai 571400,Hainan,China;Department of Cardiology,General Hosipital of Guangzhou Military Commard of PLA,Guangzhou 510180,Guangdong,China)

机构地区：[1]空军军医大学学员一旅,陕西西安710032 [2]解放军广州军区总医院心内二区,广东广州510180 [3]西安医学院心内科,陕西西安710032 [4]琼海市人民医院心内科,海南琼海571400

出　　处：《心脏杂志》2018年第6期713-715,共3页Chinese Heart Journal

摘　　要：目的观察常规治疗加用左西孟旦对慢性进展性心力衰竭的疗效。方法由广州总医院及琼海市人民医院收治的150例慢性进展性心衰患者在对症及常规抗心衰药物的基础上给予左西孟旦治疗,疗程28 d。观察治疗前后心功能指标的变化,并注意药物副作用的发生情况。结果左西孟旦治疗后,77. 3%患者左室舒张末期内径(LVEDD)较给药前显著缩小由(57±6) mm降至(49±5) mm(P <0. 01);左房内径(LAD)由(40±4) mm降至(34±5) mm(P <0. 01);左室射血分数(LVEF)由(32±5)%增加至(40±8)%(P <0. 01),血清N末端脑钠尿肽原(NT-proBNP)水平由(3. 3±1. 6) ng/ml降至(1. 9±1. 2) ng/ml(P <0. 01)。其中11例患者出现不良反应,不良反应发生率为0. 73%。结论常规治疗加用左西孟旦治疗慢性进展性心力衰竭有显著疗效,安全性好。AIM To observe the efficacy of routine therapy combined with levosimendan in the treatment of chronic progressive heart failure. METHODS 150 chronic progressive heart failure patients selected by General Hospital of Guangzhou Military Command of PLA and Qionghai people hospital were treated with levosimendan for 28 days with symptomatic and conventional anti-heart failure drugs. Changes in cardiac function index before and after the treatment were observed, and side effects of the drugs were documented. RESULTS After levosimendan treatment, the left ventrieular end-diastolic dimension （LVEDD） in 77. 3% patients significantly decreased when compared with cardiac state before administration, LVEDD decreased from （57±6） mm to （49±5） mm （P 〈0.01） ; Left atrial diameter diminished from （40±4） mm to （34±5） mm. The left ventricular ejection fraction increased from （32 ＋5）% to （40±8 ） % （ P〈0.01 ）, and serum NT-proBNP levels decreased from （ 3.3±1.6 ） ng/ml to （ 1.9±1.2 ） ng/ml （P〈0.01）. Eleven patients showed adverse reactions, the incidence of adverse reactions was 0.73%. CONCLUSION Therapy combined with levosimendan has a significant therapeutic effect on chronic progressive heart failure, which can effectively relieve ventrieular remodeling and has a good safety profile.

关 键 词：左西孟旦 心力衰竭 进展性 慢性 

分 类 号：R541.6[医药卫生—心血管疾病]